Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has submitted a 510(k) application to the FDA for expanded organism and antimicrobial ...
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of ...
Pancreatic ductal adenocarcinoma — the most common form of pancreatic cancer — is among the deadliest cancers worldwide, with a five-year survival rate of only 8%, largely because it is diagnosed at ...
Ensuring fair drug pricing was a key promise of Sri Lanka’s government’s election manifesto, and that promise is finally ...
FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to ...
(MENAFN- GlobeNewsWire - Nasdaq) FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Infant ...
WASHINGTON — Federal officials have approved another generic version of the abortion pill mifepristone, a regulatory formality that quickly triggered pushback from anti-abortion groups and politicians ...
The Food and Drug Administration on Tuesday quietly approved a generic form of mifepristone, one of the two medications used in most U.S. abortions. That makes the drug, from the company Evita ...
Federal health officials are warning Americans to avoid sunscreens marketed in whipped, mousse and foam because they aren't approved as effective methods for applying the product. The Food and Drug ...
Ocular plans to outline clinical trial design, timing, and development strategy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) at its Investor Day on September 30, ...
Doptelet is approved for pediatric thrombocytopenia, offering a new sprinkle formulation for children under six years old. The AVA-PED-301 study showed 27.8% achieved durable platelet response, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback